Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 35 of the 93 sources its claims cite were checked for support.
Abstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action.
Overview
CoChat Summary
## TL;DR
This review argues that GLP-1-based therapies have anti-inflammatory effects beyond glucose lowering, with evidence across diabetes, vascular disease, brain disorders, liver disease, nephropathy, and other inflammatory conditions. It summarizes in vitro, animal, and some human findings showing reductions in inflammatory cytokines, immune-cell infiltration, and related signaling pathways.
## Key findings
- In diabetes, GLP-1-based therapies reduced inflammatory mediators in islets and adipose tissue: liraglutide (100 nM) inhibited palmitate-induced TNF-α, IL-1β, and IL-6 in mouse islets; sitagliptin (100 mg/day) reduced plasma CRP, IL-6, IL-18, secreted phospholipase-A2, soluble ICAM-1, and E-selectin in type 2 diabetes patients, while the inflammatory score and HOMA index for insulin resistance were also significantly reduced.
- In vascular disease, liraglutide reduced adhesion molecules in endothelial cells and exendin-4 reduced atherosclerosis in mice; for example, exendin-4 (50 μg/kg/day) reduced atherosclerosis development and monocyte adhesion in APOE*3-Leiden.CETP mice, and sitagliptin reduced plaque macrophage infiltration and MMP-9 in ApoE−/− mice.
- In neurodegenerative disease models, liraglutide reduced activated microglia and inflammatory responses in Alzheimer’s disease models, and exendin-4 (10 μg/kg) decreased MPTP-induced microglial activation and TNF-α/IL-1β in Parkinson’s disease models.
- In other conditions, liraglutide improved asthma-related inflammation (including lower E-selectin, TNF-α, IL-4, IL-5, and IL-13) and exenatide improved sperm quality in diet-induced obese mice by suppressing testicular TNF-α, MCP-1, and F4/80.
## Methods
- Narrative review of published in vivo and in vitro studies on GLP-1, GLP-1 receptor agonists, and DPP-4 inhibitors across inflammatory diseases.
- Evidence base includes cell models, rodent and other animal models, and selected human studies (for example, patients with type 2 diabetes and nonalcoholic steatohepatitis).
- Main analysis was qualitative synthesis of anti-inflammatory effects and molecular mechanisms, organized by disease area and signaling pathways.
## Limitations
- The paper states that some reported benefits “need to be validated by clinical studies” for asthma, and that the safety of GLP-1-based therapy should be validated by “sufficient further studies” because rare cases of acute pancreatitis and neoplasms have been reported.
- Evident from the text: this is a review, so many conclusions are based on preclinical or small clinical studies rather than a single controlled synthesis or meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
26 Valid · 0 Not valid · 23 Not checked · 23 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 2. Diabetes
What the sources say
- Partly supportedcites [37] matched to “Diabetes and beta cell function: from mechanisms to evaluation and clinical implications” (2013) sourceExperimental — accuracy not yet measured
The “Autoimmunity and inflammation” section (page not provided) says high glucose and free fatty acids induce islet inflammation that contributes to beta-cell impairment and apoptosis. The “Adipokines” section says some adipose-derived factors promote inflammation and beta-cell failure. The paper does not establish that inflammation mediates insulin resistance, so that part of the attributed claim is unsupported. (LLM, conf=0.84)
- Partly supportedcites [38] matched to “β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment” (2014) sourceExperimental — accuracy not yet measured
The “Metabolic and Oxidative Stress” passage links glucotoxicity and lipotoxicity to β-cell damage. The “Inflammation” passage describes local islet inflammation in type 2 diabetes and says anti-inflammatory treatment can preserve some β-cell functional mass. Our copy does not establish that inflammation mediates insulin resistance or damage caused by adipose-derived adipokines, and it leaves the origin of islet inflammation unresolved. The indexed passages provide no page numbers. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [39] matched to “Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes” (2005) source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Therefore, suppression of CXCL10 production by exendin-4 could reduce islet inflammation by decreasing cytotoxic T lymphocyte recruitment into the islets in autoimmune type 1 diabetes [48].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 2. Diabetes
What the sources say
- Supportedcites [48] matched to “Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients” (2010) source
The paper's own Results ("Suppression of IFN-γ-induced CXCR3-binding chemokines by exendin-4 and cyclic AMP in human islets") show exendin-4 suppressing CXCL10 mRNA (~30% with rolipram, modest but significant with exendin-4 alone) and protein (38%), with reduced secretion into the medium, and the Introduction states that "CXCL10 plays an important role in trafficking effector T cells to islets during insulitis in type 1 diabetes" and that "suppression of CXCL10 production in islets could be an important therapeutic approach to reducing insulitis in type 1 diabetes." The citing sentence's hedged inference ("could reduce islet inflammation by decreasing ... T lymphocyte recruitment") reproduces that same reasoning, with "cytotoxic T lymphocyte" standing in for the source's CXCR3-bearing effector/activated T cells and NK cells. The source is in vitro human islets and MIN6 cells, so the type 1 diabetes benefit remains a stated possibility in both documents, not a demonstrated outcome. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Partly supportedcites [12] matched to “Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4” (2010) sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports GLP-1 receptor expression in lung, pancreatic β-cells, and endothelial cells; the introductory text also refers broadly to neural cells. The paper does not establish receptor expression in the kidney, heart, hypothalamus, astrocytes, or microglia, nor does it identify neurons specifically. Its discussion of GLP-1 effects on the heart is not evidence of receptor expression there. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [13] matched to “Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.” (1992) source
- Not checked — no full text of the sourcecites [14] matched to “The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential” (2014) source
- Not checked — no full text of the sourcecites [15] matched to “Pulmonary GLP-1 Receptor Increases at Birth and Exogenous GLP-1 Receptor Agonists Augmented Surfactant-Protein Levels in Litters From Normal and Nitrofen-Treated Pregnant Rats” (2013) source
- Not checked — no full text of the sourcecites [16] matched to “Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites” (1995) source
- Not checked — no full text of the sourcecites [17] matched to “Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes” (2006) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, GLP-1 therapy may be beneficial for the treatment of chronic inflammatory diseases including nonalcoholic steatohepatitis, atherosclerosis, neurodegenerative disorders, diabetic nephropathy, asthma, and psoriasis [14, 26–32].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [14] matched to “The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential” (2014) source
- Partly supportedcites [26] matched to “Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice” (2012) sourceExperimental — accuracy not yet measured
Vittone et al. (2012) supports only the atherosclerosis element of the list: the Discussion (p. 6) states that sitagliptin 'decreases plaque macrophage content and stabilises arteriosclerotic lesions in Apoe -/- mice, while GLP-1 directly inhibits monocyte migration and macrophage MMP-9 production in vitro', and the same passage notes broadly that 'there is evidence of anti-inflammatory effects of GLP-1 in different tissues'. Our copy makes no claim that GLP-1 therapy is beneficial in nonalcoholic steatohepatitis, diabetic nephropathy or asthma (searched: those terms plus 'chronic inflammatory diseases'); neurodegenerative and psoriatic disease appear only as titles of cited works (refs 25 and 26, References p. 9), not as conditions this paper shows GLP-1 treats. The remaining diseases in the citing list must rest on the other citations in the cluster [14, 26–31]. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [27] matched to “The role of glial cells in Parkinsonʼs disease” (2001) source
- Not checked — no full text of the sourcecites [28] matched to “Glucagon‐like peptide‐1 preserves non‐alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress‐associated pathway” (2016) source
- Not checked — no full text of the sourcecites [29] matched to “Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1” (2011) source
- Not checked — no full text of the sourcecites [30] matched to “Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice” (2014) source
- Partly supportedcites [31] matched to “Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis” (2011) sourceExperimental — accuracy not yet measured
The Conclusions/interpretation and Discussion (pages not provided) suggest therapeutic potential for GLP-1 in inflammatory conditions such as psoriasis, based on improvement observed in patients. The Discussion also mentions cardiovascular and neuroprotective effects, but the paper does not support the full list of proposed treatments, particularly nonalcoholic steatohepatitis, diabetic nephropathy, and asthma. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [32] matched to “Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells” (2013) source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“emerging data suggest that GLP-1-based therapies also showed anti-inflammatory effects on the liver, vascular system including aorta and vein endothelial cells, brain, kidney, lung, testis, and skin by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues [17, 21–25].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [17] matched to “Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes” (2006) source
- Partly supportedcites [21] matched to “Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation” (2014) sourceExperimental — accuracy not yet measured
The GLP-1RAs AND INFLAMMATION section reports anti-inflammatory effects in endothelial cells and reduced inflammatory-cytokine release; the IL-6 and chemokines sections report reductions in the liver, brain, and kidney. The monocytes/macrophages section reports reduced macrophage infiltration in adipose tissue, not across the listed organs. The cited passages do not establish anti-inflammatory effects in the aorta, lung, testis, or skin. Page numbers were not available in our copy. (LLM, conf=0.88)
- Could not verifycites [22] matched to “Anti-proliferative effect of pro-inflammatory cytokines in cultured β cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1” (2008) sourceExperimental — accuracy not yet measured
Our copy of Blandino-Rosano et al. (2008) is confined to rat pancreatic islet/β-cell culture: the Abstract and the results section 'GLP-1 has a protective role against anti-proliferative effects of cytokines' show GLP-1 reversing IL-1β/IFN-γ/TNF-α-induced ERK1/2 inactivation and restoring β-cell proliferation, and the Discussion frames this as possible use in early-stage DM1. No passage addresses anti-inflammatory actions of GLP-1-based therapies in liver, aorta/vein endothelium, brain, kidney, lung, testis or skin, nor reduced cytokine production or immune-cell infiltration in those tissues (searched: extrapancreatic tissues/endothelial/kidney/anti-inflammatory in vivo; inflammatory cytokine production and immune infiltration). Since our copy neither states nor contradicts the tissue-level claim, it cannot be verified from this source. (LLM, conf=0.70)
- Partly supportedcites [23] matched to “A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules” (2009) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [24] matched to “The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain” (2013) source
- Partly supportedcites [25] matched to “Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals” (2014) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
47 more claims · 13 with their cited sources checked
Create a free account to see all 72 claims and to verify the 6 references still open.
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs have effects on systemic inflammation such as reduction in high-sensitivity C-reactive protein (hs-CRP) that are not mediated by weight loss or glycemic control [15, 27, 28].”
From evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is increasing evidence that GLP-1RAs act as modulators of atherosclerosis, 76 and their anti-inflammatory and antioxidant properties may contribute to this, as supported by laboratory studies. 77,78”
The cited source says what the claim attributes to it.
In the citing paper
“Experimental and translational data support anti‐inflammatory and antioxidant actions of GLP‐1RAs beyond glycemic control [5].”
The cited source says what the claim attributes to it.
In the citing paper
“These benefits suggest important non‐glycemic effects, including modulation of inflammatory and vascular pathways [5].”
The cited source says what the claim attributes to it.
In the citing paper
“GLP‐1 receptor signalling may inhibit pro‐inflammatory transcriptional pathways, attenuate oxidative stress, improve endothelial function and modulate immune cell activation [5, 10].”
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Nonalcoholic steatohepatitis [61, 93, 96]”
Cited work 10.1007/s00125-010-1831-8 · retracted 2011-12-15 · notice 10.1007/s00125-011-2394-z · this paper published 2016
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 3×
“Nonalcoholic steatohepatitis [61, 93, 96]”
BackgroundRetractedRole of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“GLP-1 has many beneficial effects on the control of blood glucose levels including stimulation of insulin secretion and inhibition of glucagon secretion, expansion of the beta-cell mass by stimulating beta-cell proliferation and differentiation and inhibiting beta-cell apoptosis, delay of gastric emptying, and reducti…”
BackgroundMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes
Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s97 · Cited by 1,491
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335c1 · Cited by 1,425
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Cited by
Items 301–400 of 501
Park, S.-H., Yoon, J.-H., Seo, D. Y., Kim, T. N., Ko, J. R., & Han, J. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16050830 · Cited by 9
“GLP-1R is expressed in several cells and organs, including the hypothalamus, kidney, lung, heart, endothelial cells, neurons, and pancreas [33].”
BackgroundChan, D., Lin, Y.-C., Tzeng, H.-P., Yang, R., Chiang, M., & Liu, S. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102479 · Cited by 10
GLP-1 and IL-6 regulates obesity in the gut and brain
Yang, K., Wu, Y., He, Y., Dai, J.-X., Luo, Y.-L., Xie, J.-H., & Ding, W. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123339 · Cited by 8
Gul, U., Aung, T., Martin, M., Farrukh, D. N., Shah, P., Lovely, Z. S., León, E. M., Alansaari, M., Maini, S., Fariduddin, M. M., et al. (2024) · Cureus · doi:10.7759/cureus.76519 · Cited by 16
Machida, A., Suzuki, K., Nakayama, T., Miyagi, S., Maekawa, Y., Murakami, R., Uematsu, M., Kitaoka, T., & Oishi, A. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.5.15 · Cited by 11
Popovic, D. S., Παπάνας, Ν., Koufakis, T., Kotsa, K., Almahmeed, W. A., Al‐Rasadi, K., Al-Alawi, K., Banach, M., Banerjee, Y., Ceriello, A., et al. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2019-1111 · Cited by 9
“Endogenous GLP-1 has been shown to possess important anti-inflammatory properties that are beyond the scope of this review [68, 70].”
BackgroundGuo, J., Zhang, X., Pan, R., Zheng, Y., Chen, W., & Wang, L. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2384897 · Cited by 11
“Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by intestinal L cells that reduces blood glucose by stimulating islet β cells to secrete insulin [11].”
Thapa, D., Patil, M., Warne, L. N., Carlessi, R., & Falasca, M. (2025) · Pharmaceuticals · doi:10.3390/ph18020148 · Cited by 10
Role of the DNA repair genes H2AX and HMGB1 in human fat distribution and lipid profiles
Rohde, K., Rønningen, T., Poulsen, L. L. C., Keller, M., Blüher, M., & Böttcher, Y. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000831 · Cited by 9
Westwell-Roper, C. Y., Best, J. R., Elbe, D., MacFadden, M., Baer, S., Tucker, L., Au, A., Naqqash, Z., Lin, B., Lu, C., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054296 · Cited by 9
A Research Update on Exendin-4 as a Novel Molecule Against Parkinson’s Disease
Singh, N. K., Singh, A., Varshney, M., & Agrawal, R. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230529093314 · Cited by 10
Lee, J., Li, Y., Cheng, J., Liu, I.-M., & Cheng, K. (2024) · Pharmaceuticals · doi:10.3390/ph17040538 · Cited by 7
“The statistical significance was defined as p < 0.05.”
InfluentialCOVID-19 and Diabetes: Persistent Cardiovascular and Renal Risks in the Post-Pandemic Landscape
Huang, T.-S., Chao, J.-Y., Chang, H.-H., Lin, W.-R., & Lin, W.-H. (2025) · Life · doi:10.3390/life15050726 · Cited by 9
“GLP-1RAs suppress pro-inflammatory cytokines such as IL-6 and TNF-α , reducing pulmonary inflammation and cytokine storm severity [65,66].”
Zhang, J., Guan, X., Kong, M.-W., Xia, M., Yu, Y., & Zhang, C. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156433 · Cited by 9
Republished: DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis
Padron, S., Rogers, E., Beckler, M. D., & Kesselman, M. M. (2019) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2019.228981rep · Cited by 8
Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice
Zhang, H., Dong, M., Yuan, S., & Jin, W. (2022) · Biotechnology Letters · doi:10.1007/s10529-022-03288-1 · Cited by 8
“It was reported that GLP-1 based therapy could improves inflammatory status of type 2 diabetes (Lee and Jun 2016).”
BackgroundZishen Pill alleviates diabetes in Db/db mice via activation of PI3K/AKT pathway in the liver
Wu, Y., Sun, B., Guo, X., Wu, L., Hu, Y.-M., Qin, L., Yang, T., Li, M., Qin, T., Jiang, M., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00683-8 · Cited by 7
Monda, V. M., Voci, C., Strollo, F., Passaro, A., Greco, S., Monesi, M., Bigoni, R., Porcellati, F., Piani, D., Satta, E., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01472-8 · Cited by 7
Toxicity profile of honey and ghee, when taken together in equal ratio
Aditi, P., Srivastava, S., Pandey, H. K., & Tripathi, Y. B. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.04.002 · Cited by 11
Shepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome
Afrin, L. B., Weinstock, L. B., Dempsey, T. T., Aschenbrenner, K., Blitshteyn, S., & Schofield, J. R. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.07.006 · Cited by 7
Megerian, M. F., Reddy, R. P., Kim, B. I., White, A. E., Miller, M., Gulotta, L. V., Fu, M. C., & Taylor, S. A. (2025) · Seminars in Arthroplasty JSES · doi:10.1053/j.sart.2025.05.006 · Cited by 9
Amen, T. B., Ibrahim, L. I., Gillinov, S. M., Torabian, K. A., Dean, M. C., Liimakka, A. P., & Lee, S. K. (2025) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2025.08.004 · Cited by 7
Podder, V., Coleman, R. L., Hagemann, A. R., Singhania, P., Powell, M. A., Herzog, T. J., & Slomovitz, B. M. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2819 · Cited by 12
Thapa, D., Patil, M., Warne, L. N., Carlessi, R., & Falasca, M. (2024) · Cells · doi:10.3390/cells13232013 · Cited by 10
Smith, M., Williams, G. P., & Barker, R. N. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035378 · Cited by 6
Kim, J. H. (2020) · Physiological Research · doi:10.33549/physiolres.934480 · Cited by 7
Seo, S. H., Lee, D., Lee, S., & Choi, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-25315-x · Cited by 6
Incretin Hormones in the Control of Immunometabolism
Fishman, S., Zvibel, I., & Varol, C. (2019) · Immunometabolism · doi:10.20900/immunometab20190004 · Cited by 6
“including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis (reviewed in [94]).”
BackgroundTou, A. M., & Panganiban, J. A. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70242 · Cited by 11
Polymeri, A., Feres, M., Giannobile, W. V., & Loos, B. G. (2026) · Journal of Periodontology · doi:10.1002/jper.70092 · Cited by 14
Wang, Z.-Q., Zhang, J., Tang, X., & Zhou, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111882 · Cited by 6
EL-MOETY, M. D. H. A. E.-K. D. A., & Attia, M. A. (2018) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2018.56345 · Cited by 5
Potential Use of Biomarkers for the Clinical Evaluation of Sarcoidosis
Mousapasandi, A., Herbert, C. A., & Thomas, P. S. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001659 · Cited by 5
Gao, H., Zhao, Q., Tang, S., Li, K., Qin, F., Song, Z., Pan, Y., Jin, L., & Zhang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83201-4 · Cited by 5
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases
Miyazaki, R., & Miyagi, K. (2023) · Renal Replacement Therapy · doi:10.1186/s41100-023-00492-1 · Cited by 5
“[23] stated that GLP1RAs bind to the GLP-1 receptor and block activation of PKC or NF-κB, which in turn inhibits NLRP3, IL-1, IL-6, VCAM-1, IFN-γ and MCP-1, thereby demonstrating anti-inflammatory properties.”
BackgroundExendin-4 imaging based on gastrointestinal GLP-1R targets for IBD diagnosis and efficacy assessment
Li, X., Liu, Y., Zhang, Z., Hai, W., Pan, Y., & Zhang, Y. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07197-z · Cited by 6
“The interaction between GLP-1 and GLP-1R triggers diverse physiological effects, including gastrointestinal immunomodulatory functions [ 3 ].”
Expression kinetics reveal the self-adaptive role of β cells during the progression of diabetes
Srivastava, S., Pandey, H. K., & Tripathi, Y. B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.168 · Cited by 5
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
Teragawa, H., Morimoto, T., Fujii, Y., Ueda, T., Sakuma, M., Shimabukuro, M., Arasaki, O., Node, K., Nomiyama, T., & Ueda, S. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s282968 · Cited by 7
Jiang, X. X., Lan, L., Zhou, Q., et al. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-000690 · Cited by 5
Rella, S., Onyiah, J. C., Baker, C., Singh, V., Her, A., & Rasouli, N. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231207348 · Cited by 6
“33,59 In animal studies, administration of GLP-1 therapies in obese and diabetic mice resulted in improved intestinal barrier function by decreasing intestinal inflammation and expediting mucosal healing, in addition to lowering blood glucose.”
BackgroundInfluentialThe Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
“75,76 Another prominent aspect is pain modulation, and some of the newer anti-obesity medication candidates obtained from salmon calcitonin are especially of significant interest in this respect.”
Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
Dauleh, H., Mohammed, I., & Hussain, K. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf266 · Cited by 4
“Additionally, it exerts anti-inflammatory and cardioprotective effects through adenosine monophosphate–activated protein kinase C and SIRT1 activation, which inhibit nuclear factor κ B signaling and reduce oxidative stress [15].”
Yahyavi, A., Nikoo, M. Z., Hussein, L., Katara, A., Perez, J. A., & Shishehbor, M. H. (2025) · Vascular Medicine · doi:10.1177/1358863x251393107 · Cited by 6
“26,27 GLP-1RA medications have been proposed to exert a direct beneficial effect on lower-limb perfusion.”
Zein nanoparticles extend lifespan in C. elegans and SAMP8 mice
Martínez‐López, A. L., Reboredo, C., González-Navarro, C. J., Solas, M., Puerta, E., Ramírez, M. J., Vizmanos, J. L., & Irache, J. M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124798 · Cited by 4
Impact of medical versus surgical weight loss on cardiovascular outcomes
Ostapenko, A., & Ahmed, B. H. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.03.004 · Cited by 5
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 6
The Neuroprotective Effect of NEUROMIDE, a Compound Bioidentical to Commensal Bacteria Metabolites
Seo, Y., Tak, H., Park, D., Song, H., Choe, S., Park, C., & Park, B. D. (2022) · Life · doi:10.3390/life12101529 · Cited by 4
“In addition, GLP-1 has also been reported to have important anti-inflammatory properties with potential for treating chronic inflammatory diseases, such as type 1 and type 2 diabetes mellitus, asthma, psoriasis, and neurodegenerative disorders [30].”
BackgroundAmelioration of Phytanic Acid–Induced Neurotoxicity by Nutraceuticals: Mechanistic Insights
Neha, N., Chaudhary, S., Tiwari, P., & Parvez, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03985-0 · Cited by 5
GLP‐1: A Prospective Guardian for Comprehensive Myocardial Perfusion
Li, Z., Yu, Y., Li, J., Jiang, X., Chen, J., Ye, N., Wu, B., Sun, Y., & Sun, G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70004 · Cited by 5
“Besides, local vascular inflammation is a key contributor to endothelial cell dysfunction and impaired vasodilation [40].”
Thapa, D., Ghimire, A., Warne, L. N., & Carlessi, R. (2025) · Pharmaceuticals · doi:10.3390/ph18040478 · Cited by 6
“Growing evidence suggests a complex interplay between GLP-1 and eCBome in regulating metabolism, gut homeostasis, and inflammation, making them promising therapeutic targets for IBD-associated metabolic disorders [173,178–180].”
DPPIV/CD26 as a Target in Anti-inflammatory Therapy
Vliegen, G., & Meester, I. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805417-8.00011-1 · Cited by 6
Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials
Barbarawi, M., Aburahma, A., Zayed, Y., Osman, M., Rashdan, L., Swaid, B., & Bachuwa, G. I. (2018) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2018.1542919 · Cited by 5
Moon, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020118 · Cited by 5
“Moreover, GLP-1 can control the inflammatory and oxidative stress occurring during metabolic renal disorders [94,95].”
BackgroundMomoi, Y., Saita, Y., Nagao, M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061484 · Cited by 4
Hui‐Yuen, J. S., Jiang, K., Malkiel, S., Eberhard, B. A., Walters, H. M., Diamond, B., & Jarvis, J. N. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000921 · Cited by 4
Alshanwani, A. R., Kashour, T., & Badr, A. M. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210809153558 · Cited by 8
Álvarez, S., Contreras‐Kallens, P., Aguayo, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.21.501009 · Cited by 4
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Böhm, E. W., Omran, W., Zadeh, J. K., Arad, T., Pfeiffer, N., Patzak, A. R., Oelze, M. W., Daiber, A., Helmstädter, J., Steven, S., et al. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110562 · Cited by 4
Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases
Chamchoum, E., Katrib, N., Nassif, N., Ratel, Y., & Rida, M. A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i3.107020 · Cited by 7
Anti-inflammatory strategies for patients with atherosclerotic coronary disease
Imbesi, A., Greco, A., & Capodanno, D. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2564137 · Cited by 6
“In fact, GLP-1 RAs mitigate systemic inflammation by reducing hs-CRP, IL-6, and TNF-α while enhancing endothelial function [159,160].”
Rayner, B. L., Mahaffey, K. W., Mann, J. F. E., Pratley, R. E., Rossing, P. R., Belmar, N., Bosch‐Traberg, H., Jeppesen, O. K., Tran, M. C., Chernin, G., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag036 · Cited by 5
“GLP-1-based therapies may have anti-inflammatory effects in people with chronic inflammatory diseases [ 26 ].”
Naik, H. B., & Thiara, D. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.1882 · Cited by 3
Acute Heart Failure: Transitioning From Symptom-Based Care to Remission
Cotter, G., Davison, B. A., Mann, D. L., Biegus, J., ter Maaten, J. M., Pagnesi, M., Freund, Y., Voors, A. A., Ponikowski, P. P., Metra, M., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.12.016 · Cited by 6
Ayash, R., Kabalan, Y., & Chamaa, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177708 · Cited by 3
Diabetes Mellitus and Infections
Zhou, K., & Lansang, M. C. (2021) · Europe PMC (PubMed Central) · Cited by 4
Arrhythmia prevalence and sudden death risk in adults with the m.3243A>G mitochondrial disorder
Bourke, J. P., Ng, Y. S., Tynan, M., et al. (2022) · Open Heart · doi:10.1136/openhrt-2021-001819 · Cited by 3
Effects of A GLP‑1 Receptor Agonist on Gastrointestinal Epithelial Cells
Takizawa, Y., Oguri, J., Uno, M., Onsui, A., Ishimura, A., Kurita, T., & Nakajima, T. (2022) · Scholars Academic Journal of Pharmacy · doi:10.36347/sajp.2022.v11i04.002 · Cited by 3
“GLP-1 receptor agonists not only exert therapeutic effects on diabetes, they have also been reported to exhibit anti-inflammatory activity in humans and rodent pathological models [5, 6, 7], improve lipid metabolism and promote weight loss in patients with”
BackgroundCOVID-19 and Diabetes Mellitus: Mutual Interplay of Two Diseases
Krumpolec, P., Kodada, D., Nyáriová, N., Repiská, V., & Minárik, G. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666220913113146 · Cited by 3
Severity of Symptoms and Mortality in Diabetic Patients with COVID- 19 Infection. Review
Albasry, Z., Rashid, A. A., & Abbas, S. H. (2023) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v23i1.991 · Cited by 3
Castro, M. C., Villagarcía, H. G., Schinella, G. R., Massa, M. L., & Francini, F. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159363 · Cited by 4
Special Issue: “Anti-inflammatory Effects of Glucagon-like Peptide-1”
Puddu, A., & Maggi, D. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041997 · Cited by 7
Supramanian, K., Sekar, M., & Afendi, N. S. H. N. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005083 · Cited by 8
Ölmestig, J. N. E., Marlet, I. R., Vilsbøll, T., Rungby, J., Rostrup, E., Lambertsen, K. L., & Kruuse, C. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899389 · Cited by 4
“Inflammation appears to play an important role in several acute and chronic diseases, including vascular diseases and diabetes and could be a potential treatment target (Lee and Jun, 2016).”
BackgroundInfluentialFerri, G., Tesi, M., Pesce, L., Bugliani, M., Grano, F., Occhipinti, M., Suleiman, M., Luca, C. D., Marselli, L., Marchetti, P., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091403 · Cited by 5
“, oleate) might be played by stimulating pro‐survival and/or anti‐inflammatory mechanisms [40,41].”
BackgroundEnteric pathogens modulate metabolic homeostasis in the Drosophila melanogaster host
Najjar, H., Al-Ashmar, S. A., Qush, A., et al. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.104946 · Cited by 3
Thapa, D., Patil, M., Warne, L. N., Carlessi, R., & Falasca, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167913 · Cited by 3
“GLP-1, an incretin hormone, despite its glucose regulatory and anti-inflammatory actions, is also implicated in several intestinal diseases, including IBD [41,70].”
Davis, W. R., Bank, N. C., Lauck, B. J., Creighton, R. A., & Mistovich, R. J. (2025) · JSES Reviews Reports and Techniques · doi:10.1016/j.xrrt.2025.100613 · Cited by 4
“3,9,19,24 Despite this growing body of literature, limited data exist regarding the impact of GLP-1RAs specifically on the shoulder joint, which biomechanically differs from weight-bearing joints of the lower extremities and remains under-investigated.”
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
The Hidden Link Between Endometriosis and Obesity: A State-of-the-Art Review
Desai, S., Reed, C. C., Mendez, Y. H., Yang, Q., & Guan, X. (2026) · Cureus · doi:10.7759/cureus.102896 · Cited by 4
“It is a polypeptide chain of 30 amino acids and is categorized as an incretin hormone because it is secreted from L cells in response to nutrient ingestion [52,53].”
Chávez, J. C. P., Dobricic, M., McGrath, M., O’Connor, C., McGuire, T. K., Maughan, J., Dervan, A. G., Dixon, J. E., Kearney, C. J., Browne, S., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.02.004 · Cited by 9
Khalifa, O., & Arredouani, A. (2026) · Pharmaceuticals · doi:10.3390/ph19030408 · Cited by 8
Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift
Maranta, F., Cianfanelli, L., Gaspardone, C., Rizza, V., Grippo, R., Ambrosetti, M., & Cianflone, D. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.05.050 · Cited by 2
Antidiabetic agents: Do they hit the right targets?
Zhao, Y., Zhang, X., Liang, H., & Wang, L. (2022) · Frigid Zone Medicine · doi:10.2478/fzm-2022-0030 · Cited by 2
Kihara, K., Kinoshita, M., Sugimoto, T., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330478 · Cited by 2
The Potential Protective Effect of Vildagliptin on Paw Edema: An Experimental Study
Alkabbani, M. A., Amer, W., Mustafa, A., & Faheem, S. (2023) · ERU Research Journal · doi:10.21608/erurj.2023.216079.1040 · Cited by 2
Weight loss with GLP-1 analogues in preparation for transplantation
O’Callaghan, M., le Roux, C. W., Fabre, A., & McCarthy, C. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-256099 · Cited by 2
“13 In bleomycin-treated mice models, GLP-1 analogues have been shown to reduce overexpression of TGF-β 1 and α -SMA, two key drivers of fibrosis and myofibroblast transition.”
BackgroundAbood, A., Awad, H., & Hassan, S. M. (2021) · Ain Shams Medical Journal · doi:10.21608/asmj.2021.167313 · Cited by 3
“GLP-1 based therapies have been shown to modulate inflammation at multiple sites, including the kidneys and blood vessels (67) .”
BackgroundYang, Y., Zhao, L., Wang, Y., Liu, C., & Ke, T. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01228-x · Cited by 2
“In COVID-19, GLP-1RA is conducive to reducing cytokine-induced lung injury by interfering with the NF-kB pathway, or exerting anti-inflammatory effects [43, 44].”
Ghosal, S., & Sinha, B. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200206113549 · Cited by 2
ATM-mediated DNA damage response in macrophages primes phagocytosis and immune checkpoint regulationPreprint
Bansal, A., Neuhaus, R., Izquierdo, E., Vorholt, D., Feldkötter, H., Nolte, H., Lohneis, P., Büttner, R., Krüger, M., Pallasch, C. P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.14.987438 · Cited by 3
Relevance of Sex-Specific Metabolic Phenotypes in Diagnosis and Treatment of Mood Disorders and PTSD
Henry, S. S., Ross, R., & Rasgon, N. (2022) · Psychiatric Annals · doi:10.3928/00485713-20211221-01 · Cited by 1
Greco, S., Monda, V. M., Valpiani, G., Napoli, N., Crespini, C., Pieraccini, F., Marra, A. R., & Passaro, A. (2023) · Biomedicines · doi:10.3390/biomedicines11082292 · Cited by 3
“When these mechanisms malfunction, as is the case in T2DM, uncontrolled glucose homeostasis leads to chronic inflammation [15].”
BackgroundSrour, L., Ismail, J., Njeim, R., & Eid, A. A. (2024) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-031-62131-4_8 · Cited by 2
Reversal of inflammatory reprogramming by vasodilator agents in pulmonary hypertension
Kirillova, A., Sethuraman, M., Dong, X., Kirdar, A., Speyer, G., Aaraj, Y. A., Watson, A. M. M., Schneider, L. K., Creager, M. D., Lafyatis, R., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00486-2024 · Cited by 2
Šalamun, V., Lovrečić, L., Maver, A., Peterlin, B., Frangež, H. B., Riemma, G., Laganà, A. S., Herman, R., Janež, A., Bokal, E. V., et al. (2025) · Gynecologic and Obstetric Investigation · doi:10.1159/000547513 · Cited by 2
“This is consistent with liraglutide’s known stimulation of insulin and inhibition of glucagon secretion, both relevant in glucose regulation [31].”
Abdelnabi, M. H., Chaisrimaneepan, N., Castillo‐Rodriguez, C., Eshak, N., Sullivan, M. M., Ibrahim, R., Pham, H. N., Farina, J., Ayoub, C., Nagaraja, V., et al. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01124-z · Cited by 1
Péč, M. J., Jurica, J., Péčová, M., Nagy, N., Focko, B., Miertová, Z., Ferencová, N., Ságová, I., Tonhajzerová, I., Bolek, T., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091364 · Cited by 4
“Compensatory response to insulin resistance is chronic hyperinsulinemia, which is primarily driven by adiposity and chronic systemic inflammation [29–31].”
Park, A. K., Hom, J., Lorenzo, J., Rao, V. K., Hui, G., Vickers, M., & Ahuja, N. K. (2025) · Journal of Hospital Medicine · doi:10.1002/jhm.70228 · Cited by 2
Metadata
- Authors
- Lee, Y.-S., & Jun, H.-S.
- Affiliations
- Gachon University (KR)
- Corresponding author
- Jun, Hee-Sook
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-11
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4823510
- OpenAlex
- W2306319461
- Cited by
- 530
- References
- 116
- Citations by year
- 2026: 68 · 2025: 83 · 2024: 56 · 2023: 52 · 2022: 60 · 2021: 72 · 2020: 53 · 2019: 47 · 2018: 21 · 2017: 15 · 2016: 3
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (2015R1D1A1A01060232)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, DPP-4 inhibitors, anti-inflammatory activity, chronic inflammation, type 2 diabetes, type 1 diabetes, atherosclerosis, neurodegenerative diseases, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, psoriasis, glucose homeostasis, molecular mechanisms of inflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Inflammation, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.